

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,078,403 B1
APPLICATION NO. : 10/018963
DATED : July 18, 2006
INVENTOR(S) : Wen-Yang Wu et al.

Page 1 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 42

Line 67, the phrase "hydrogen, di(C₁₋₆alkylamino, cyano, formyl" should read as --hydrogen, C₁₋₆alkyl, halo, hydroxyl, mercapto, haloC₁₋₄alkyl, amino, mono (C₁₋₆alkylamino), di(C₁₋₆alkyl)amino, cyano, formyl--.

Column 43

Line 14, the phrase "is O, SO or SO₂" should read as --is O, S, SO or SO₂ --.

Column 44


Line 47, the term "-CH₂)₂-" should read as -- -(CH₂)₂- --.

Column 44

Line 48, the term "-CH₂)₂O-" should read as -- -CH₂O- --.

Column 45

Lines 17-25, the formula




Column 45

Line 35, the term "C₁₋₆-alkyl" should read as --C₁₋₆alkyl--.

Line 36, the term "cashe" should read as --each--.

Lines 47-55, the formula



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,078,403 B1
APPLICATION NO. : 10/018963
DATED : July 18, 2006
INVENTOR(S) : Wen-Yang Wu et al.

Page 2 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 48

Line 62-63, the compound name "1-(4-{2-[1-Chloro-pyridazin-3-yl]-piperidin-4yl}-ethoxy}-phenyl)-propan-1-one O-allyl-oxime" should read as --1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4yl]-ethoxy}-phenyl)-propan-1-one O-allyl-oxime--.

Column 49

Line 16-17, the compound name "3-Methly-4-{2-1-(methyl-pyridazin-3-yl)-piperidin-4-yl-ethoxy}-benzaldehyde O-methyl oxime" should read as --3-Methly-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl-ethoxy]-benzaldehyde O-methyl oxime--.

Column 50

Line 62-63, the compound name "3-[1-(Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde O-allyl-oxime" should read as --3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde O-allyl-oxime--.

Column 51

Line 18-19, the compound name "4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4yl]-ethoxy}-indan-1-one O-ethyl-oxime" should read as --4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-indan-1-one O-ethyl-oxime--.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,078,403 B1
APPLICATION NO. : 10/018963
DATED : July 18, 2006
INVENTOR(S) : Wen-Yang Wu et al.

Page 3 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


Column 52

Line 4-5, the compound name "3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde O-2-oxo-propyl)-oxime" should read as --3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy-benzaldehyde O-(2-oxo-propyl)-oxime--.

Lines 16-17, the compound name "3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-3,5-dimethyl-benzaldehyde O-(2-fluoro-ethyl)-oxlme" should read as --3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)- propoxy]-benzaldehyde O-(2-fluoro-ethyl)-oxime--.

Signed and Sealed this

Twentieth Day of November, 2007

A handwritten signature in black ink, reading "Jon W. Dudas", is written over a rectangular area with a light, dotted background pattern.

JON W. DUDAS
Director of the United States Patent and Trademark Office